1565P - Lung cancer in patients under 40 years: A prospective observational multicenter study (Groupe Français de Pneumo-Cancérologie (GFPC) 1001 study)

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Thoracic Malignancies
Cancers in Adolescents and Young Adults (AYA)
Presenter Laurence Bigay-Gamé
Citation Annals of Oncology (2014) 25 (suppl_4): iv542-iv545. 10.1093/annonc/mdu357
Authors L. Bigay-Gamé1, S. Bota2, L. Greillier3, I. Monnet4, A. Madroszyk5, R. Corre6, B. Mastroianni7, L. Falchero8, C. Chouaid9, C. Audigier-Valette10, N. Baize11, C. Daniel12, G. Fraboulet13, D. Gossot14, C. Raynaud15, J. Mazières16, H. Colineaux17, B. Lepage18, G. Robinet19
  • 1Department Of Thoracic Oncology, Hopital Larrey, CHU Toulouse, 31059 - TOULOUSE/FR
  • 2Pulmonology Department, CHU Rouen, Rouen/FR
  • 3Multidisciplinary Oncology & Therapeutic Innovations, Aix-Marseille Univ, Assistance Publique-Hôpitaux de Marseille, Marseille/FR
  • 4Pulmonology, Centre Hospitalier intercommunal de creteil, 94010 - creteil/FR
  • 5Department Of Medical Oncology, Institut Paoli Calmettes, Marseille/FR
  • 6Pulmonology Department, CHU Pontchaillou, rennes/FR
  • 7Pulmonology Department, CHU Lyon, Lyon/FR
  • 8Pulmonology Department, Centre Hospitalier de Villefranche-sur-Saône, Villefranche-sur-Saône/FR
  • 9Pneumologie, Pneumologie, APHP, 75012 - paris/FR
  • 10Pulmonology Department, Centre Hospitalier de Toulon, Toulon/FR
  • 11Pneumologie, C.H.U. Angers, 49933 - ANGERS/FR
  • 12Department Of Medical Oncology, Institut Curie, Paris/FR
  • 13Pulmonology Department, centre Hospitalier de Pontoise, Pontoise/FR
  • 14Department Of Thoracic Oncology, Institut Mutualiste Montsouris, Paris/FR
  • 15Pulmonology Department, Centre Hospitalier d'Argenteuil, Argenteuil/FR
  • 16Thoracic Oncology, Larrey, Toulouse University Hospital, Toulouse/FR
  • 17Service D'épidémiologie, CHU Toulouse, Toulouse/FR
  • 18Cict, CHU Toulouse - CICT, 31000 - toulouse/FR
  • 19Department Of Medical Oncology, C.H.U. MorvanInstitut de Cancerologie et d'Hematologie, FR-29609 - Brest CEDEX /FR



Lung cancer in patients under 40 years is infrequent and few data are available about the presentation and outcomes of lung cancer in this population. This study aimed to describe the clinical characteristics, the treatments and the outcome of lung cancer occurring in the population of young adults in France.


A prospective observational clinical study was conducted in 37 centers in France. All patients under 40 years diagnosed with lung cancer between November 2010 and December 2013 were enrolled.


One hundred and fifty nine patients with lung cancer were included. Intermediate results are currently available for 117 patients. Median age at diagnosis was 38 (20-40). The proportion of men was 58%. Median time between symptoms and diagnosis was 2 months. The distribution of stages I- II, IIIA and IIIB-IV was 9%, 9% and 82% respectively; 66% were diagnosed with metastasis at presentation and the first metastasis site was brain in 47% of patients. Adenocarcinoma was the most common histologic subtype (78%). EGFR screening was performed for 83 patients and 10% of the patients had an activating mutation. Analysis of other driver biomarkers is ongoing. Eighty-four patients (86%) were current or former tobacco smoker with a median of 20 packs -year. Sixty-nine patients (59%) have been exposed to passive smoking essentially in childhood. About half of them (46%) were current or former cannabis smoker (among which 50% regularly). Socioeconomic status was lower comparing to general population, 24% of the patients had no diploma. The first line treatments were 88% chemotherapy, 43% radiotherapy, 21% surgery and 5% best supportive care. Median overall survival was 14.7 months.


This study is the first national prospective study dedicated to patients under 40 years diagnosed with lung cancer. Compared to the general population of lung cancer, our preliminary results show a high proportion of women, adenocarcinoma histology, advanced disease at diagnosis and tobacco and cannabis use. Final analysis will be presented at the congress.


All authors have declared no conflicts of interest.